Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

<p>Water plot of best response in lung NEN.</p>

Saved in:

書目詳細資料
主要作者:	Dwight H. Owen (15034782) (author)
其他作者:	Brooke Benner (15054338) (author), Lai Wei (15023852) (author), Vineeth Sukrithan (15054341) (author), Ashima Goyal (15054344) (author), Ye Zhou (15054347) (author), Carly Pilcher (15054350) (author), Sheryl-Ann Suffren (15054353) (author), Gwen Christenson (15054356) (author), Nancy Curtis (15054359) (author), Megan Jukich (15054362) (author), Emily Schwarz (15054365) (author), Himanshu Savardekar (15054368) (author), Ruthann Norman (15054371) (author), Sarah Ferguson (15054374) (author), Barbara Kleiber (15054377) (author), Robert Wesolowski (8863505) (author), William E. Carson (15054380) (author), Gregory A. Otterson (15054383) (author), Claire F. Verschraegen (15054386) (author), Manisha H. Shah (15054389) (author), Bhavana Konda (15054392) (author)
出版:	2025
主題:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Chemotherapy Combination chemotherapy Clinical Trial Results Phase II clinical trials Endocrine-Related Cancers Immunotherapy Checkpoint blockade Lung Cancer
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
由: John A. Ligon (15024477)
出版: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
由: Yan Zhou (15053225)
出版: (2025)

Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
由: Aurelius Omlin (14971513)
出版: (2025)

Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
由: Aurelius Omlin (14971513)
出版: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
由: Chong Kin Liam (15331321)
出版: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
由: Chong Kin Liam (15331321)
出版: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
由: Chong Kin Liam (15331321)
出版: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
由: Chong Kin Liam (15331321)
出版: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
由: Qingsheng Xu (17078830)
出版: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
由: Qingsheng Xu (17078830)
出版: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
由: Ulka N. Vaishampayan (15051039)
出版: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
由: Ulka N. Vaishampayan (15051039)
出版: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
由: Ulka N. Vaishampayan (15051039)
出版: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
由: Ulka N. Vaishampayan (15051039)
出版: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
由: Tom Wei-Wu Chen (15053003)
出版: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
由: Tom Wei-Wu Chen (15053003)
出版: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
由: Tom Wei-Wu Chen (15053003)
出版: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
由: Tom Wei-Wu Chen (15053003)
出版: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
由: Tom Wei-Wu Chen (15053003)
出版: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
由: Fabrice Barlesi (15045504)
出版: (2025)

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
由: Fabrice Barlesi (15045504)
出版: (2025)

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
由: Fabrice Barlesi (15045504)
出版: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
由: Fabrice Barlesi (15045504)
出版: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
由: Fabrice Barlesi (15045504)
出版: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
由: Roger Li (17078665)
出版: (2025)

Supplementary Figure 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
由: Michelle L. Mierzwa (14963463)
出版: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
由: Giuseppe Basile (15051269)
出版: (2025)

Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
由: Andrés Elía (15055031)
出版: (2025)

Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
由: Andrés Elía (15055031)
出版: (2025)

Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
由: Andrés Elía (15055031)
出版: (2025)

Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
由: Andrés Elía (15055031)
出版: (2025)

Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
由: Andrés Elía (15055031)
出版: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
由: Nigel Bundred (15046233)
出版: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
由: Nigel Bundred (15046233)
出版: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
由: Nigel Bundred (15046233)
出版: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
由: Nigel Bundred (15046233)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_mrik2pilckd5e21jmbm7tf10df